[Targeted therapies for metastatic colorectal cancer].
Targeted therapies against vascular endothelial growth factor (VEGF), VEGF receptor and epidermal growth factor receptor (EGFR) have improved survival in patients with metastatic colorectal cancer (mCRC). Clinical studies have demonstrated that the following 6 targeted agents showed antitumor activity in patients with mCRC: bevacizumab, aflibercept, ramucirumab, cetuximab, panitumumab and regorafenib. KRAS exon 2 (codons 12 and 13) mutations were negative predictive biomarkers for efficacy of anti-EGFR antibody therapy. Expanded RAS mutations (including KRAS exon 2, exon 3 and exon 4 mutations as well as NRAS mutations) can further predict the therapeutic effects of this therapy. It seems to be necessary to identify new predictive biomarkers and develop new targeted agents for personalized treatment for mCRC.
Yosuke
Y
Kito
Kentaro
K
Yamazaki
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000068258:Bevacizumab; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D066246:ErbB Receptors; D005091:Exons / Q000235:genetics; D005544:Forecasting; D006801:Humans; D058990:Molecular Targeted Therapy; D009154:Mutation; D009364:Neoplasm Recurrence, Local; D000077544:Panitumumab; D010671:Phenylurea Compounds / Q000627:therapeutic use; D011518:Proto-Oncogene Proteins / Q000235:genetics; D016283:Proto-Oncogene Proteins p21(ras); D011725:Pyridines / Q000627:therapeutic use; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A; D018631:ras Proteins / Q000235:genetics; D000096662:Ramucirumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D000068818:Cetuximab; D066246:ErbB Receptors; D000077544:Panitumumab; D010671:Phenylurea Compounds; D011518:Proto-Oncogene Proteins; D016283:Proto-Oncogene Proteins p21(ras); D011725:Pyridines; D040262:Receptors, Vascular Endothelial Growth Factor; D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A; D018631:ras Proteins; D000096662:Ramucirumab; C117307:KRAS protein, human; C467484:VEGFA protein, human; C533178:aflibercept; C559147:regorafenib; C512478:EGFR protein, human